The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Targeting signal transduction as a strategy to treat inflammatory diseases
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease
Hugot, J.-P., Chamaillard, M., Zouali, H., Lesage, S., Cézard, J.-P., Belaiche, J., Almer, S., Tysk, C., O'Morain, C. A., Gassull, M., et al. (2001) · Nature · doi:10.1038/35079107 · Cited by 5,591
Gout-associated uric acid crystals activate the NALP3 inflammasome
Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A., & Tschopp, J. (2006) · Nature · doi:10.1038/nature04516 · Cited by 5,326
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease
Ogura, Y., Bonen, D. K., Inohara, N., Nicolae, D. L., Chen, F. F., Ramos, R., Britton, H., Moran, T., Karaliuskas, R., Duerr, R. H., et al. (2001) · Nature · doi:10.1038/35079114 · Cited by 5,030
A protein kinase involved in the regulation of inflammatory cytokine biosynthesis
Lee, J. C., Laydon, J. T., McDonnell, P. C., Gallagher, T. F., Kumar, S., Green, D., McNulty, D., Blumenthal, M. J., Keys, J. R., Land vatter, S. W., et al. (1994) · Nature · doi:10.1038/372739a0 · Cited by 3,288
Cryopyrin activates the inflammasome in response to toxins and ATP
Mariathasan, S., Weiss, D. S., Newton, K., McBride, J., O'Rourke, K., Roose-Girma, M., Lee, W. P., Weinrauch, Y., Monack, D. M., & Dixit, V. M. (2006) · Nature · doi:10.1038/nature04515 · Cited by 3,080
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
IKKε and TBK1 are essential components of the IRF3 signaling pathway
Fitzgerald, K. A., McWhirter, S. M., Faia, K. L., Rowe, D. C., Latz, E., Golenbock, D. T., Coyle, A. J., Liao, S.-M., & Maniatis, T. (2003) · Nature Immunology · doi:10.1038/ni921 · Cited by 2,676
A MAP Kinase Targeted by Endotoxin and Hyperosmolarity in Mammalian Cells
Han, J., Lee, J.-D., Bibbs, L., & Ulevitch, R. J. (1994) · Science · doi:10.1126/science.7914033 · Cited by 2,646
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Interleukin-17 Family Members and Inflammation
Kolls, J. K., & Lindén, A. (2004) · Immunity · doi:10.1016/j.immuni.2004.08.018 · Cited by 2,372
Inducibility of κ immunoglobulin enhancer-binding protein NF-κB by a posttranslational mechanism
Sen, R., & Baltimore, D. (1986) · Cell · doi:10.1016/0092-8674(86)90807-x · Cited by 1,993
Chromatin–IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors
Leadbetter, E. A., Rifkin, I. R., Hohlbaum, A. M., Beaudette, B. C., Shlomchik, M. J., & Marshak-Rothstein, A. (2002) · Nature · doi:10.1038/416603a · Cited by 1,900
Agostini, L., Martinon, F., Burns, K., McDermott, M. F., Hawkins, P. N., & Tschopp, J. (2004) · Immunity · doi:10.1016/s1074-7613(04)00046-9 · Cited by 1,768
Triggering the Interferon Antiviral Response Through an IKK-Related Pathway
Sharma, S., tenOever, B. R., Grandvaux, N., Zhou, G.-P., Lin, R., & Hiscott, J. (2003) · Science · doi:10.1126/science.1081315 · Cited by 1,661
Osborn, L., Kunkel, S., & Nabel, G. J. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.7.2336 · Cited by 1,621
The IKK NF-κB system: a treasure trove for drug development
Karin, M., Yamamoto, Y., & Wang, Q. M. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1279 · Cited by 1,364
Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3
Kanneganti, T.-D., Özören, N., Body-Malapel, M., Amer, A., Park, J.-H., Franchi, L., Whitfield, J., Barchet, W., Colonna, M., Vandenabeele, P., et al. (2006) · Nature · doi:10.1038/nature04517 · Cited by 1,148
Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators
Staels, B., Koenig, W., Habib, A., Merval, R., Lebret, M., Torra, I. P., Delerive, P., Fadel, A., Chinetti, G., Fruchart, J.-C., et al. (1998) · Nature · doi:10.1038/31701 · Cited by 1,134
Kremer, J. M., Westhovens, R., Leon, M., Di Giorgio, E., Alten, R., Steinfeld, S., Russell, A., Dougados, M., Emery, P., Nuamah, I. F., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035075 · Cited by 1,058
A physical and functional map of the human TNF-α/NF-κB signal transduction pathway
Bouwmeester, T., Bauch, A., Ruffner, H., Angrand, P.-O., Bergamini, G., Croughton, K., Cruciat, C., Eberhard, D., Gagneur, J., Ghidelli, S., et al. (2004) · Nature Cell Biology · doi:10.1038/ncb1086 · Cited by 1,029
Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6
Häcker, H., Redecke, V., Blagoev, B., Kratchmarova, I., Hsu, L.-C., Wang, G. G., Kamps, M. P., Raz, E., Wagner, H., Häcker, G., et al. (2006) · Nature · doi:10.1038/nature04369 · Cited by 968
Natalizumab Induction and Maintenance Therapy for Crohn's Disease
Sandborn, W. J., Colombel, J. F., Enns, R., Feagan, B. G., Hanauer, S. B., Lawrance, I. C., Panaccione, R., Sanders, M., Schreiber, S., Targan, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043335 · Cited by 927
Interleukin-17 family and IL-17 receptors
Moseley, T. A., Haudenschild, D. R., Rose, L., & Reddi, A. H. (2003) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(03)00002-9 · Cited by 918
Spatiotemporal regulation of MyD88–IRF-7 signalling for robust type-I interferon induction
Honda, K., Ohba, Y., Yanai, H., Negishi, H., Mizutani, T., Takaoka, A., Taya, C., & Taniguchi, T. (2005) · Nature · doi:10.1038/nature03547 · Cited by 912
Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response
Oganesyan, G., Saha, S. K., Guo, B., He, J. Q., Shahangian, A., Zarnegar, B., Perry, A., & Cheng, G. (2006) · Nature · doi:10.1038/nature04374 · Cited by 881
IKK/NF- B signaling: balancing life and death - a new approach to cancer therapy
Luo, J.-L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26322 · Cited by 878
Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of hsp27
Freshney, N. W., Rawlinson, L., Guesdon, F., Jones, E., Cowley, S., Hsuan, J., & Saklatvala, J. (1994) · Cell · doi:10.1016/0092-8674(94)90278-x · Cited by 864
Signalling pathways and molecular interactions of NOD1 and NOD2
Strober, W., Murray, P. J., Kitani, A., & Watanabe, T. (2006) · Nature Reviews Immunology · doi:10.1038/nri1747 · Cited by 856
NOD2 is a negative regulator of Toll-like receptor 2–mediated T helper type 1 responses
Watanabe, T., Kitani, A., Murray, P. J., & Strober, W. (2004) · Nature Immunology · doi:10.1038/ni1092 · Cited by 840
Lau, C. M., Broughton, C., Tabor, A. S., Akira, S., Flavell, R. A., Mamula, M. J., Christensen, S. R., Shlomchik, M. J., Viglianti, G. A., Rifkin, I. R., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050630 · Cited by 812
Nod2 Mutation in Crohn's Disease Potentiates NF-κB Activity and IL-1ß Processing
Maeda, S., Hsu, L.-C., Liu, H., Bankston, L. A., Iimura, M., Kagnoff, M. F., Eckmann, L., & Karin, M. (2005) · Science · doi:10.1126/science.1103685 · Cited by 749
TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo
Shim, J.-H., Xiao, C., Paschal, A. E., Bailey, S. T., Rao, P., Hayden, M. S., Lee, K.-Y., Bussey, C., Steckel, M., Tanaka, N., et al. (2005) · Genes & Development · doi:10.1101/gad.1360605 · Cited by 738
NLRs join TLRs as innate sensors of pathogens
MARTINON, F., & TSCHOPP, J. (2005) · Trends in Immunology · doi:10.1016/j.it.2005.06.004 · Cited by 673
Molecular determinants of crosstalk between nuclear receptors and toll-like receptors
Ogawa, S., Lozach, J., Benner, C., Pascual, G., Tangirala, R. K., Westin, S., Hoffmann, A., Subramaniam, S., David, M., Rosenfeld, M. G., et al. (2005) · Cell · doi:10.1016/j.cell.2005.06.029 · Cited by 647
New Drugs for Rheumatoid Arthritis
Olsen, N. J., & Stein, C. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032906 · Cited by 626
Small-Molecule Inhibition of TNF-α
He, M. M., Smith, A. S., Oslob, J. D., Flanagan, W. M., Braisted, A. C., Whitty, A., Cancilla, M. T., Wang, J., Lugovskoy, A. A., Yoburn, J. C., et al. (2005) · Science · doi:10.1126/science.1116304 · Cited by 620
Drosophila Toll and IL-1 receptor
GAY, N. J., & KEITH, F. J. (1991) · Nature · doi:10.1038/351355b0 · Cited by 619
How Toll-like receptors signal: what we know and what we don’t know
O’Neill, L. A. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2005.11.012 · Cited by 613
Self-citationPrevention of organ allograft rejection by a specific Janus kinase 3 inhibitor
Changelian, P. S., Flanagan, M. E., Ball, D. J., Kent, C. R., Magnuson, K. S., Martin, W. H., Rizzuti, B. J., Sawyer, P. S., Perry, B. D., Brissette, W. H., et al. (2003) · Science · doi:10.1126/science.1087061 · Cited by 607
Targeting JNK for therapeutic benefit: from junk to gold?
Manning, A. M., & Davis, R. J. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1132 · Cited by 585
O'Neill, L. A. J., & Greene, C. (1998) · Journal of Leukocyte Biology · doi:10.1002/jlb.63.6.650 · Cited by 561
Self-citationJanssens, S., & Beyaert, R. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00053-4 · Cited by 559
Cyclic GMP Phosphodiesterase-5: Target of Sildenafil
Corbin, J. D., & Francis, S. H. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.20.13729 · Cited by 531
The Toll–IL-1 receptor adaptor family grows to five members
O'Neill, L. A. J., Fitzgerald, K. A., & Bowie, A. G. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(03)00115-7 · Cited by 491
Self-citationMoynagh, P. N. (2005) · Journal of Cell Science · doi:10.1242/jcs.02579 · Cited by 489
Uematsu, S., Sato, S., Yamamoto, M., Hirotani, T., Kato, H., Takeshita, F., Matsuda, M., Coban, C., Ishii, K. J., Kawai, T., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042372 · Cited by 488
Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1
Kassel, O. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.7108 · Cited by 479
TNFα—A PIVOTAL ROLE IN RHEUMATOID ARTHRITIS?
BRENNAN, F. M., MAINI, R. N., & FELDMANN, M. (1992) · Rheumatology · doi:10.1093/rheumatology/31.5.293 · Cited by 386
Lasa, M., Abraham, S. M., Boucheron, C., Saklatvala, J., & Clark, A. R. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.22.7802-7811.2002 · Cited by 382
The Poxvirus Protein A52R Targets Toll-like Receptor Signaling Complexes to Suppress Host Defense
Harte, M. T., Haga, I. R., Maloney, G., Gray, P., Reading, P. C., Bartlett, N. W., Smith, G. L., Bowie, A., & O'Neill, L. A. J. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021652 · Cited by 370
Self-citationBonizzi, G., Bebien, M., Otero, D. C., Johnson‐Vroom, K. E., Cao, Y., Vu, D., Jegga, A. G., Aronow, B. J., Ghosh, G., Rickert, R. C., et al. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600391 · Cited by 338
Dean, J. L. E., Sully, G., Clark, A. R., & Saklatvala, J. (2004) · Cellular Signalling · doi:10.1016/j.cellsig.2004.04.006 · Cited by 307
A new modality for immunosuppression: targeting the JAK/STAT pathway
O'Shea, J. J., Pesu, M., Borie, D. C., & Changelian, P. S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1441 · Cited by 303
Expression and Regulation of Toll-Like Receptor 2 in Rheumatoid Arthritis Synovium
Seibl, R., Birchler, T., Loeliger, S., Hossle, J. P., Gay, R. E., Saurenmann, T., Michel, B. A., Seger, R. A., Gay, S., & Lauener, R. P. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63918-1 · Cited by 287
Amelioration of Experimental Autoimmune Encephalomyelitis in Lewis Rats by FTY720 Treatment
Fujino, M., Funeshima, N., Kitazawa, Y., Kimura, H., Amemiya, H., Suzuki, S., & Li, X.-K. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.045658 · Cited by 280
Control of lymphocyte development by nuclear factor-κB
Siebenlist, U., Brown, K., & Claudio, E. (2005) · Nature Reviews Immunology · doi:10.1038/nri1629 · Cited by 272
Targeting interleukin‐15 in patients with rheumatoid arthritis: A proof‐of‐concept study
Baslund, B., Tvede, N., Danneskiold‐Samsoe, B., Larsson, P., Panayi, G., Petersen, J., Petersen, L. J., Beurskens, F. J. M., Schuurman, J., van de Winkel, J. G. J., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21249 · Cited by 265
Phosphodiesterase inhibitors in airways disease
Fan Chung, K. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.12.059 · Cited by 243
TRANSCRIPTIONAL AND POST-TRANSCRIPTIONAL CONTROL OF GENE EXPRESSION IN INFLAMMATION
Kracht, M., & Saklatvala, J. (2002) · Cytokine · doi:10.1006/cyto.2002.0895 · Cited by 229
Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases
O'Neill, L. A. J. (2003) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(03)00080-8 · Cited by 167
Self-citationContext-specific inhibition of JNKs: overcoming the dilemma of protection and damage
WAETZIG, V, & HERDEGEN, T. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.07.006 · Cited by 166
p38 MAP kinase inhibitors: many are made, but few are chosen.
Dominguez, C., Powers, D. A., & Tamayo, N. A. (2005) · PubMed · Cited by 163
Chiba, K., Matsuyuki, H., Maeda, Y., & Sugahara, K. (2006) · PubMed · Cited by 158
Jun N-Terminal Kinase in Rheumatoid Arthritis
Han, Z., Boyle, D. L., Aupperle, K. R., Bennett, B. L., Manning, A. M., & Firestein, G. S. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35079-7 · Cited by 157
GOLDSTEIN, D. M., & Gabriel, T. (2005) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026054985939 · Cited by 150
Wietek, C., Miggin, S. M., Jefferies, C. A., & O'Neill, L. A. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308135200 · Cited by 135
Self-citationPPAR‐gamma modulates allergic inflammation through up‐regulation of PTEN
Lee, K. S., Park, S. J., Hwang, P. H., Yi, H. K., Song, C. H., Chai, O. H., Kim, J., Lee, M. K., & Lee, Y. C. (2005) · The FASEB Journal · doi:10.1096/fj.04-3309fje · Cited by 135
Bartfai, T., Behrens, M. M., Gaidarova, S., Pemberton, J., Shivanyuk, A. N., & REBEK, J. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932746100 · Cited by 132
Rdp58 Is a Novel and Potentially Effective Oral Therapy for Ulcerative Colitis
Travis, S. P. L., Yap, L. M., Hawkey, C., Warren, B. F., Lazarov, M. E., Fong, T., & Tesi, R. J. (2005) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000172807.26748.16 · Cited by 121
Inhibitors of the mammalian target of rapamycin
Dancey, J. E. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.3.313 · Cited by 99
Cardiovascular hazard and non-steroidal anti-inflammatory drugs
Wong, D., Wang, M., Cheng, Y., & FitzGerald, G. A. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.02.001 · Cited by 95
Meglio, P. D., Ianaro, A., & Ghosh, S. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20960 · Cited by 87
The role of IL-17 and family members in the pathogenesis of arthritis.
Lubberts, E. (2003) · PubMed · Cited by 73
Unraveling the NALP-3/IL-1β Inflammasome
Dinarello, C. A. (2004) · Immunity · doi:10.1016/s1074-7613(04)00055-x · Cited by 58
McCoy, S. L., Kurtz, S. E., MacArthur, C. J., Trune, D. R., & Hefeneider, S. H. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.5.3006 · Cited by 57
Bissonnette, R., Papp, K. A., Poulin, Y. P., Lauzon, G. J., Aspeslet, L. J., Huizinga, R. B., Mayo, P., Foster, R. T., Yatscoff, R. W., & Maksymowych, W. P. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.10.061 · Cited by 56
Preclinical Profile of Ciclesonide, a Novel Corticosteroid for the Treatment of Asthma
Belvisi, M. G., Bundschuh, D. S., Stoeck, M., Wicks, S., Underwood, S. L., Battram, C. H., Haddad, E., Webber, S. E., & Foster, M. L. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.085217 · Cited by 54
YOUNG, D., & Nickerson‐Nutter, C. L. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.03.004 · Cited by 42
Effect of rapamycin on the cyclosporin A–resistant CD28-mediated costimulatory pathway
Ghosh, P., Buchholz, M. A., Yano, S., Taub, D. D., & Longo, D. L. (2002) · Blood · doi:10.1182/blood-2001-11-0062 · Cited by 39
Pralnacasan (vertex pharmaceuticals).
Siegmund, B., & Zeitz, M. (2003) · PubMed · Cited by 28
New Advances and Potential Therapies for the Treatment of Asthma
Belvisi, M. G., Hele, D. J., & Birrell, M. A. (2004) · BioDrugs · doi:10.2165/00063030-200418040-00001 · Cited by 22
Lehle, K., Birnbaum, D. E., & Preuner, J. G. (2005) · Transplantation Proceedings · doi:10.1016/j.transproceed.2004.12.140 · Cited by 17
Cited by
LPS/TLR4 signal transduction pathway
Lu, Y.-C., Yeh, W.-C., & Ohashi, P. S. (2008) · Cytokine · doi:10.1016/j.cyto.2008.01.006 · Cited by 3,301
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling
O'Neill, L. A. J., & Bowie, A. G. (2007) · Nature Reviews Immunology · doi:10.1038/nri2079 · Cited by 2,667
Self-citationInterferons at age 50: past, current and future impact on biomedicine
Borden, E. C., Sen, G. C., Uze, G., Silverman, R. H., Ransohoff, R. M., Foster, G. R., & Stark, G. R. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2422 · Cited by 1,154
Targeting Toll-like receptors: emerging therapeutics?
Hennessy, E. J., Parker, A. E., & O'Neill, L. A. J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3203 · Cited by 886
Self-citation
Metadata
- Authors
- O'Neill, L. A. J.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-06-09
- Volume
- 5
- Issue
- 7
- Pages
- 549-563
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2168165195
- Cited by
- 283
- References
- 83
- FWCI
- 1.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.